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Abstract
Background: Mowat–Wilson syndrome (MWS; OMIM #235730) is a genetic condition caused by heterozygous
mutations or deletions of the ZEB2 gene. It is characterized by moderate-severe intellectual disability, epilepsy,
Hirschsprung disease and multiple organ malformations of which congenital heart defects and urogenital
anomalies are the most frequent ones. To date, a clear description of the physical development of MWS patients
does not exist. The aim of this study is to provide up-to-date growth charts specific for infants and children with
MWS. Charts for males and females aged from 0 to 16 years were generated using a total of 2865 measurements
from 99 MWS patients of different ancestries. All data were collected through extensive collaborations with the
Italian MWS association (AIMW) and the MWS Foundation. The GAMLSS package for the R statistical computing
software was used to model the growth charts. Height, weight, body mass index (BMI) and head circumference
were compared to those from standard international growth charts for healthy children.
Results: In newborns, weight and length were distributed as in the general population, while head circumference
was slightly smaller, with an average below the 30th centile. Up to the age of 7 years, weight and height
distribution was shifted to slightly lower values than in the general population; after that, the difference increased
further, with 50% of the affected children below the 5th centile of the general population. BMI distribution was
similar to that of non-affected children until the age of 7 years, at which point values in MWS children increased
with a less steep slope, particularly in males. Microcephaly was sometimes present at birth, but in most cases it
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developed gradually during infancy; many children had a small head circumference, between the 3rd and the 10th
centile, rather than being truly microcephalic (at least 2 SD below the mean). Most patients were of slender build.
Conclusions: These charts contribute to the understanding of the natural history of MWS and should assist
pediatricians and other caregivers in providing optimal care to MWS individuals who show problems related to
physical growth. This is the first study on growth in patients with MWS.
Keywords: Mowat-Wilson syndrome, ZEB2, Growth charts, Weight, Length, Height, Head circumference, Body mass
index, BMI
Background
Mowat-Wilson syndrome (MWS; OMIM #235730) is a
rare autosomal dominant disorder caused by haploinsuf-
ficency in the ZEB2 gene located on chromosome 2. It is
characterized by distinctive facial features, moderate-to-
severe intellectual disability, epilepsy, Hirschsprung dis-
ease and multiple congenital anomalies, including genital
anomalies, congenital heart defects, agenesis of the cor-
pus callosum and eye defects. Since the first report in
1998, more than 350 individuals have been described in
the literature [1–8].
The incidence of MWS is estimated to be 1:50.000–
70.000 live births [9].
Several studies have reported the presence of short
stature in MWS patients. In a recent article [7], which
included the clinical data of 87 patients with MWS, we
demonstrated that basic growth parameters - weight,
length or height, body mass index (BMI), head circum-
ference - are often normal at birth, but have a tendency
to descend well below the normal range in childhood
and later on. These results urged us to extend our study
and construct growth charts specific for MWS.
Growth charts specific for a disease are fundamental
instruments in order to monitor growth and observe de-
viations from normal patterns [10–20]. They allow clini-
cians to advise parents concerning growth expectations
Fig. 1 Constructed length and height growth charts for MWS patients in relation to the CDC reference charts (black) for males (blue)
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for their children, and they can be very useful even in a
group of patients for whom growth anomalies are not
the most severe problem. Moreover, these charts de-
scribe the natural history of the disease.
The aim of this study was to provide a growth refer-
ence for MWS patients. We collected the measurements
of 99 MWS patients from 20 countries and developed
specific growth charts that describe the natural history
of height, weight, BMI and head circumference in MWS.
Methods
Study population
Growth data of MWS patients previously published by
our workgroup were incorporated into this study [7]. An
invitation to participate in the study, explaining its pur-
pose and design, was sent to all our colleagues who had a
previous history of publications on MWS. Furthermore,
the Italian Mowat-Wilson Association (AIMW) and the
MWS Foundation forwarded the invitation to their mem-
bers. To those who agreed to participate, we sent a spe-
cially designed questionnaire where they could insert the
length/height, weight and head circumference measure-
ments of patients at different ages. The collected data
were reviewed and assembled in a password-protected
database. Whenever we detected inconsistencies, probable
errors or missing data, we contacted the family/referring
doctor for corrections and further information, if needed.
Only individuals with both clinical and molecular con-
firmation of the disease were included in the study. Two
patients were excluded since the causative ZEB2 variant
could not be found despite molecular testing.
A total of 20 nationalities were represented in this
study: 38 Italian patients, 16 from the USA, 7 from
Poland, 6 from Japan, 5 from Denmark, 4 from Spain, 4
from the UK, 3 from Portugal, 3 from Finland, 2 from
Croatia, 2 from Serbia, and 1 each from Albania, Brazil,
Chile, Cyprus, France, Germany, Mexico, Turkey and
Ukraine. None of the affected individuals originated
from a consanguineous family. One Italian family com-
prised two affected siblings. None of the patients had
ever been treated with growth hormone.
A total of 99 patients were included in the study, 53
females and 46 males, born between 1986 and 2016. A
total of 2865 measurements were available: 1220 data
points from 46 males and 1645 data points from 53 fe-
males. These patients had a mean age of 12 years (range
4–20 years) in males and 13 years (range 3–23 years) in
females at the time of assessment.
A total of 1013 height measurements (573 for females,
440 for males), 1110 weight measurements (631 for
Fig. 2 Constructed length and height growth charts for MWS patients in relation to the CDC reference charts (black) for females (pink)
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females, 479 for males), and 742 head circumference
measurements (441 for females, 301 for males) were
available. We gathered measurements from at least 2
time points in 97 patients, and from more than 4 time
points in 89 patients. For each patient we had an average
of 10.39 (SD 6.52) height measurements, 11.37 (SD 6.77)
weight measurements, and 7.64 (SD 5.76) head circum-
ference measurements (Additional file 1 Table 1).
Due to limited data availability, no growth curves
could be generated for individuals with MWS past the
age of 16 years.
Data from 1986 to 2019 were included. Height, weight
and head circumference parameters were analyzed from
birth until 23 years of age, both for males and females.
BMI was calculated from these data, using the formula
BMI =mass(kg)/(height(m))2.
Distribution centiles for weight, length and head cir-
cumference at birth were computed including preterm
and at term newborns, i.e. from 32 to 42 gestational
weeks (mean 36.5), and presented separately for males
and females.
The data after birth were divided into different age
and sex groups, with 1-month intervals during the first
year of life, 3-month intervals during the 2nd and 3rd
years of life, and 6-month intervals between the 4th and
23rd years of life.
Our growth charts were compared with the reference
percentiles for anthropometric measurements in healthy
children provided by the Centers for Disease Control
and Prevention (CDC), with a few exceptions: for neo-
natal anthropometric assessment we referred to the Ital-
ian Neonatal Study (INeS) growth charts, data on head
circumference in males and females aged between 3 and
16 years were compared with the Tanner reference per-
centiles, and standard deviations of the head circumfer-
ence in males and females aged between birth and 18
years were compared with the Nellhaus reference stand-
ard deviations [21–28].
Statistical analysis
The growth charts were developed using the Generalized
Additive Models for Location, Scale and Shape
(GAMLSS) [29, 30] package for the R statistical comput-
ing software [31].
Centile estimation of anthropometric data Y (weight,
length, BMI and head circumference) for any given age
was:
Fig. 3 Constructed weight growth charts for MWS patients in relation to the CDC reference charts (black) for males (blue)
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Y  D μ; δ; ν; τð Þ
g1 μð Þ ¼ h1 xð Þ
g2 δð Þ ¼ h2 xð Þ
g3 νð Þ ¼ h3 xð Þ
g4 τð Þ ¼ h4 xð Þ
x ¼ ageξ
where the distribution D represents the best general
probability (density) function according to Akaike Infor-
mation Criterion (AIC) and μ the first parameter of the
distribution (usually location), δ the second parameter of
the distribution (usually scale, coefficient of variation), ν
the third parameter of the distribution (usually shape,
e.g. skewness), τ the fourth parameter of the distribution
(usually shape, e.g. kurtosis).
The g() functions represent appropriate link functions,
h() are non-parametric smoothing functions and ξ is a
power transformation of age (Additional file 2 Table 2).
The more traditional LMS method developed by Cole
and Green [32] can be fitted within this framework by
assuming that the response variable has a Box-Cox Cole
and Green distribution [33, 34]. Additional file 2 Table 2
describes the model specifications by anthropometric
measure and sex. The Q test was conducted to evaluate
the fit of the model [35].
The estimated centiles by age and sex were converted
back to Excel to create charts for each anthropometric
variable, including the reference CDC growth charts for
healthy children.
Results
Length, weight and head circumference at birth
Information on weight at birth was available for 47 fe-
males and 35 males. Information on length at birth was
available for 47 females and 31 males. Information on
head circumference at birth was available for 40 females
and 26 males.
The average gestational age was 39 weeks, with a range
between 32 and 42. Gestational age in MWS was com-
pletely comparable to that of the general population.
Weights at birth were found to be within the normal
range in both males and females. The average weight in
males was 3288 g, with a range between 1850 g and
4500 g; the average weight in females was 3340 g, with a
range between 1620 g and 4060 g. The birth weight of all
males was between the 2nd and 100th centiles for gesta-
tional age (mean 51st centile); the females’ birth weight
Fig. 4 Constructed weight growth charts for MWS patients in relation to the CDC reference charts (black) for females (pink)
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was between the 3rd and 100th centiles (mean 54th
centile).
Length at birth was within the normal range for the
vast majority of patients, both males and females. The
average birth length in males measured 50 cm, with a
range between 43 and 56 cm (range 2nd to 99th centile,
mean 44th centile). The average birth length in females
was 49.1 cm, with a range between 41 and 54 cm
(range < 1st to 100th centile, mean 53rd centile).
Despite the fact that in both sexes the average head
circumference at birth was within the normal range,
most patients were under the 50th centile, with mean
values at the 27th centile for males and 31st for females.
In males, the mean was 33.2 cm, with a range between
28.5 and 36 cm (<1st to 96th centile); in females, the
mean was 33.7 cm, with a range between 28.5 and 36 cm
(<1st to 100th centile).
Length and height
The mean number of longitudinal measurements per pa-
tient in males was 9.56 (SD 5.51). For 45 patients we had
at least 2 measurements, and for 40 patients we gathered
more than 4 measurements.
The mean number of longitudinal measurements per
patient in females was 11.00 (SD 7.11). For 53 patients
we had at least 2 measurements, and for 48 patients we
gathered more than 4 measurements.
Up to the age of 2 months, the length of both males
and females was within, or just below, the normal range.
Subsequently, height in males began to increase more
slowly. A significant reduction in the slope of the growth
curves was noted after 7 years of age, as the height of
boys affected by MWS became even more distant from
the reference curves of the general population (Fig. 1
and Additional file 3 Fig. RD1).
Mean height for male patients at the age of 9 years
was 121 cm (<3rd percentile, mean reference group at
50th percentile: 133 cm) and for female patients was
123.8 cm (3rd-5th percentile, mean reference group at
50th percentile: 130 cm).
In females, from 2months of age, height had a slower
increase as in males, and subsequently diverged even
further from the reference curves of the general popula-
tion. A significant reduction in the slope of the growth
charts was noted after 11 years of age, much later than
in males. At this age, females affected by MWS became
noticeably distant from the reference curves of the
Fig. 5 Constructed charts for the BMI (Kg/m2) for MWS patients in relation to the CDC reference charts (black) a for males (blue) b for
females (pink)
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general population, but were slightly less distant than
males (Fig. 2 and Additional file 4 Fig. RD2).
We were not able to extend the growth charts over
the age of 16 years due to the limited availability of mea-
surements after this age. Furthermore, it is not yet pos-
sible to calculate the final height because MWS has only
relatively recently been described and the data on ado-
lescent and young adult patients is still very limited.
Weight and body mass index
The mean number of weight measurements per patient
in males was 10.41 (SD 5.67). For 45 patients we had at
least 2 measurements and for 41 patients we gathered
more than 4 measurements.
The mean number of weight measurements per pa-
tient in females was 12.07 (SD 7.41). For 52 patients we
had at least 2 measurements and for 50 patients we col-
lected more than 4 measurements.
At age 0 to 36 months, compared to the reference
group, the growth curves for weight were slightly lower
than normal in both genders. Mean weight for male pa-
tients at age 5 years and 6months was 16.800 kg (10th
percentile, mean reference group at 50th percentile:
19.500 kg) and for female patients was 15.400 kg (10th
percentile, mean reference group at 50th percentile:
19 kg).
After this age the growth charts flatten out consider-
ably when compared to the normal reference group
(Figs. 3 and 4, Additional file 5 Fig.RD3, Additional file 6
Fig. RD4).
At the age of 16 years both male and female pa-
tients were considerably lighter (males: mean 48 kg
5th percentile, mean reference group at 50th percent-
ile: 61 Kg; females: mean 39 kg <3rd percentile, mean
reference group at 50th percentile: 54 Kg). Most pa-
tients were of slender build, with normal body
proportions.
Fig. 6 Constructed charts for the head circumference (cm) for MWS patients with age 0–3 years in relation to the CDC reference charts (black) for
males (blue)
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BMI in the age range 0 to 6 years was slightly lower
with respect to the normal reference group. Mean BMI
for male patients at 6 years of age was 15 kg/m2 (mean
reference group: 15.4 kg/m2) and for female patients was
14.9 kg/m2 (mean reference group: 15.3 kg/m2). There-
after, between the ages of 6 and 16 years, the curve for
BMI flattened out significantly in both genders, but in
males the shift of the curve towards lower values was
more pronounced and occurred earlier, at the age of 7
years, while in females it became significant after the age
of 9 years (Fig. 5).
BMI of male patients aged 16 years (mean 17.2 kg/m2)
was significantly lower compared to the reference group
(mean 20.5 kg/m2). BMI of female patients aged 16 years
(mean 17.1 kg/m2) was significantly lower compared to
the reference group (mean 20.5 kg/m2).
Head circumference
The mean number of head circumference measurements
per patient in males was 6.54 (SD 4.79). For 39 patients
we had at least 2 measurements, and for 31 patients we
collected more than 4 measurements.
The mean number of head circumference measure-
ments per patient in females was 8.54 (SD 6.23). For 51
patients we had at least 2 measurements, and for 41 pa-
tients we collected more than 4 measurements.
At birth, head circumference differed only slightly
from the reference group in both genders. Indeed, dur-
ing the first months of life, most measurements were
between the 3rd and the 25th percentile of the curves
for healthy controls. This changed after 1 year of age:
MWS patients had a significantly smaller head circum-
ference between the ages of 1 and 2 years. Between the
ages of 2 and 3 years the curves flattened out even more
and the head circumference was significantly smaller
compared to healthy controls.
Mean head circumference for male patients at age 3
years was 47 cm (5th percentile, <− 2SD, mean reference
group at 50th percentile: 50 cm) and for female patients
was 46 cm (5th percentile, − 2SD, mean reference group
at 50th percentile: 49 cm) (Figs. 6 and 7 and Add-
itional file 7 Fig. RD5 Additional file 8 Fig.RD6).
It should be noted that not all children were micro-
cephalic (at least 2 SD below the mean).
The curves for males and females continued to flatten
out in the following age ranges, up to the age of 16 years.
Adolescent male patients at the age of 16 years had a
mean head circumference of 52 cm (<3rd percentile, <−2
SD), the females had a mean head circumference of 49.8
cm (<3rd percentile, <−2SD) (Figs. 8 and 9).
Discussion
Various genetic disorders are characterized by growth
abnormalities. Specific growth charts developed for these
conditions are useful for the clinical follow-up of these
patients [10–20].
In this study, charts for height, weight, BMI and head
circumference were created using a sample of 99
Fig. 7 Constructed charts for the head circumference (cm) for MWS patients with age 0–3 years in relation to the CDC reference charts (black) for
females (pink)
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patients whose clinical diagnosis of MWS had been con-
firmed through genetic or cytogenetic testing.
Typically, children affected by MWS had normal
length and weight at birth, and then showed a growth
delay over time. The average head circumference was
already slightly smaller than in the general population at
birth (3rd-25th percentile) and showed a further delay
during growth, leading to a mean head circumference in
MWS patients below the 3rd centile of the general
population. These results indicate that intrauterine
growth retardation in MWS is not a consistent finding
in terms of length and weight, and only plays a minor
role in terms of head circumference.
In males, since the age of 2 months, the slope of the
growth curves for length underwent an initial decrease.
A significant further decrease was noted after 7 years of
age, as the values for height became markedly distant
from the reference curves of the general population. In
females we observed a similar tendency, but the delay in
the height growth chart took place considerably later,
after 11 years of age.
Through these length, weight and head circumference
growth charts we demonstrate that postnatal growth re-
tardation in MWS becomes evident after the second
month of life, is quite pronounced after 6 months and,
after 1 year of age, growth flattens out even further.
Males tend to be thinner than females and they also
tend to have a similar head circumference when com-
pared to females.
In addition, we observed the absence of the growth
spurt during adolescence, as has already been observed
in other genetic diseases, such as Turner syndrome and
SHOX-related conditions [36, 37], but we do not yet
have useful and sufficient data to calculate a final height,
Fig. 8 Constructed charts for the head circumference (cm) for MWS patients with age 3–16 years in relation to the Tanner reference charts (black)
for males (blue)
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because the definition of MWS is quite recent and
known adult individuals are still rare.
We also assessed BMI in MWS patients. BMI of male
patients aged 16 years (mean 17.2 kg/m2) was found to
be significantly lower when compared to the reference
group (mean 20.5 kg/m2). BMI of female patients aged
16 years (mean 17.1 kg/m2) was significantly lower com-
pared to the reference group (mean 20.5 kg/m2).
A limitation of the present study is the small absolute
number of available subjects, which slightly reduces the
precision of the growth curves, particularly in the ado-
lescence age range. Nevertheless, this cohort includes a
large portion of all well-described MWS patients in the
world, and including only MWS patients with a con-
firmed ZEB2 defect significantly increases the reliability
of our results by excluding any misclassification of cases.
Conclusions
The growth charts we prepared for height, weight, BMI
and head circumference may be used to assess the
growth of MWS children compared to the general
population.
Specific growth charts can be useful for pediatricians
and clinicians in evaluating growth-related issues and in
providing optimal care to MWS individuals. Further-
more, they contribute to our understanding of the nat-
ural history of MWS.
The growth charts presented here may be put to
good use all over the world, however they ought to
be used carefully in MWS individuals with other eth-
nic backgrounds. In circumstances such as these, it is
essential to consider variations according to the area
of origin.
Fig. 9 Constructed charts for the head circumference (cm) for MWS patients with age 3–16 years in relation to the Tanner reference charts (black)
for females (pink)
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